PATENT CLAIM ANALYSIS

Application Number: 15766212
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "093210"]

Abstract:
Provided herein are methods and compositions useful for treating cancer, such as prostate cancer, through adoptive cell transfer of T cells derived from patients and genetically engineered to express MDA-7/IL-24 and/or other immune modulating agents. The methods described herein result in cancer cell death and reprogramming of the tumor immune compartment to restore antitumor immunity both at a primary tumor site and systemically.

Claim (Index 21):
The method of  claim 19 , wherein said cancer is selected from the group consisting of prostate, brain, breast, pancreatic, liver, kidney, lung, spleen, gall bladder, anal, testicular, ovarian, cervical, skin, bone, blood, and colon cancer.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 91.0
- Lexical Diversity: 1.26415
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14660484', '14254235', '13240009', '14650775', '13669194']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7725859174840047
- 35 USC 102 Novelty (BERT): 0.519913891992578
- Combined Prediction Score: 0.7473187149348621
- Mean Citation Score: 302.133908
- Max Citation Score: 315.64066
- Similarity Product: 206.9723436819792

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test